ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2022年12月01日 08時30分
Source:
Eisai
エーザイ、サンアントニオ乳がんシンポジウム2022におけるエリブリンの前臨床および臨床研究に関する演題について発表
東京, 2022年12月01日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、2022年12月6日から10日まで米国テキサス州サンアントニオおよびバーチャル形式で開催される「サンアントニオ乳がんシンポジウム 2022」において、自社創製の抗がん剤エリブリンメシル酸塩(製品名:「ハラヴェン(R)」、以下 エリブリン)に関する最新知見を発表することをお知らせします。
本学会では、2 つの臨床第III相試験(EMBRACEおよび301試験)の事後サブグループ解析結果、ホルモン受容体陽性/HER2 陰性乳がん患者様を主な対象とした PI3K阻害剤投与後のエリブリンのリアルワールドにおける治療、および乳がん患者様由来の腫瘍組織移植モデルにおけるエリブリンリポソーム製剤(乳がんを対象に臨床第Ⅰ相試験拡大コホートを実施中)とエリブリンを同用量で比較した前臨床データを含む5演題を発表します。
当社チーフサイエンティフィックオフィサーである常務執行役大和隆志博士は、「我々は、乳がん患者様に有益な情報を提供するための研究を継続して実施しており、このコミットメントの一環として、エリブリンに関する前臨床および臨床データの継続的な共有に注力してまいります」と述べています。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2022/news202286.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Mitsubishi Shipbuilding Receives Order for the MAmmoSS(R) Ammonia Fuel Handling System
Jun 27, 2026 13:16 JST
MHI Study Results Indicate Potential Cost Reductions in the Decarbonization Value Chain Using Green Hydrogen and Ammonia Produced in India
Jun 27, 2026 13:00 JST
Foxconn and Sharp Signs Memorandum of Understanding for Strategic Collaboration in New Business Areas
Jun 27, 2026 12:44 JST
DENSO Group Formulates New Environmental Policy "Eco Vision 2035"
Jun 27, 2026 11:58 JST
JCB and PNB Launch New Platinum Credit Card, Empowering Consumers with Greater Value and Lifestyle Benefits
Jun 26, 2026 19:00 JST
MHIET's 500kW-Class Hydrogen Engine Generator Set Achieves Technology Readiness Level for Commercialization
Jun 24, 2026 02:29 JST
DOCOMO Becomes First in Japan to Deploy Nokia's AI-powered MantaRay AutoPilot for Automated Network Optimization
Jun 24, 2026 02:11 JST
Mitsubishi Power and LNGPH Sign Long-Term Deal for Gas Turbine Parts and Services to Advance Energy Resilience in the Philippines
Jun 24, 2026 01:54 JST
Honda to Rename Rugby Team "TOCHIGI Honda HEAT" to Coincide with the Team's New Base of Operation
Jun 24, 2026 00:36 JST
NEC Participates in NATO CCDCOE's Cyber Defense Exercise "Locked Shields 2026"
Jun 24, 2026 00:13 JST
JCB Contactless Expands to Metro de Madrid Enabling Seamless Tap-to-Ride Access Across the Network
Jun 23, 2026 12:00 JST
Fujitsu honored with record-breaking 8 awards at AWS Japan Certification Award 2025, recognized for AI and cloud implementation and talent capabilities
Jun 19, 2026 23:58 JST
Fujitsu spotlights dynamic transformation for business in an AI era as the core theme for the Fujitsu Technology and Service Vision 2026
Jun 19, 2026 23:15 JST
New Heat Dissipation Device Design Achieves a 47% Weight Reduction in an NTN Planar Antenna
Jun 19, 2026 22:39 JST
Hitachi Energy bolsters the regional transformer market with strategic investment in North America
Jun 19, 2026 22:15 JST
Japantastics Introduces Sato Mokko to the World -- A New Chapter in Japanese Artisanal Craftsmanship
Jun 18, 2026 08:00 JST
Hitachi expands its work with OpenAI to accelerate AI-driven modernization and cybersecurity
Jun 17, 2026 14:54 JST
Fujitsu and IBM Japan collaborate on modernization to support enterprise digital transformation
Jun 17, 2026 14:23 JST
Sharp to Introduce AQUOS R11 Smartphone
Jun 17, 2026 13:59 JST
Honda to Begin Supplying Three High-output Models of the eGX Electric Power Unit Series for Commercial-Grade Work Equipment
Jun 17, 2026 13:44 JST
More Latest Release >>
Related Release
Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
6/17/2026 1:28:00 PM JST
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
5/22/2026 12:23:00 AM JST
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
4/21/2026 8:52:00 PM JST
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
3/27/2026 8:14:00 PM JST
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
3/27/2026 6:19:00 PM JST
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
3/23/2026 11:19:00 AM JST
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
3/19/2026 10:54:00 AM JST
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
3/17/2026 7:49:00 PM JST
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
3/12/2026 5:21:00 PM JST
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
3/11/2026 12:07:00 PM JST
More Press release >>